Yang Zheng, Gong Daoqing, He Xinxiang, Huang Fei, Sun Yi, Hu Qinming
Department of Infectious Disease, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, China.
Teaching Office, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, China.
Front Nutr. 2023 Feb 13;10:1113789. doi: 10.3389/fnut.2023.1113789. eCollection 2023.
Metabolic associated fatty liver disease (MAFLD) has become the most common liver disease globally, yet no new drugs have been approved for clinical treatment. Therefore, we investigated the relationship between dietary intake of soy-derived daidzein and MAFLD, to find potentially effective treatments.
We conducted a cross-sectional study using data from 1,476 participants in National Health and Nutrition Examination Survey (NHANES) from 2017 to 2018 and their associated daidzein intake from the flavonoid database in the USDA Food and Nutrient Database for Dietary Studies (FNDDS). We investigated the relationship between MAFLD status, controlled attenuation parameter (CAP), AST/Platelet Ratio Index (APRI), Fibrosis-4 Index (FIB-4), liver stiffness measurement (LSM), nonalcoholic fatty liver disease (NAFLD) fibrosis score (NFS), hepatic steatosis index (HSI), fatty liver index (FLI), and daidzein intake by adjusting for confounding variables using binary logistic regression models and linear regression models.
In the multivariable-adjusted model II, there was a negative association between daidzein intake and the incidence of MAFLD (OR for Q4 versus Q1 was 0.65, 95% confidence interval [CI] = 0.46-0.91, = 0.0114, for trend was 0.0190). CAP was also negatively associated with daidzein intake, = -0.37, 95% CI: -0.63 to -0.12, = 0.0046 in model II after adjusting for age, sex, race, marital status, education level, family income-to-poverty ratio (PIR), smoking, and alcohol consumption. Stratified by quartiles of daidzein intake, trend analysis of the relationship between daidzein intake and CAP remained significant ( for trend = 0.0054). In addition, we also found that HSI, FLI, and NFS were negatively correlated with daidzein intake. LSM was negatively related to daidzein intake but had no statistical significance. The correlation between APRI, FIB-4, and daidzein intake was not strong (although < 0.05, β values were all 0).
We found that MAFLD prevalence, CAP, HSI, and FLI, all decreased with increased daidzein intake, suggesting that daidzein intake may improve hepatic steatosis. Therefore, dietary patterns of soy food or supplement consumption may be a valuable strategy to reduce the disease burden and the prevalence of MAFLD.
代谢相关脂肪性肝病（MAFLD）已成为全球最常见的肝脏疾病，但尚无新药获批用于临床治疗。因此，我们研究了大豆衍生的大豆苷元的饮食摄入量与MAFLD之间的关系，以寻找潜在的有效治疗方法。
我们使用了2017年至2018年美国国家健康与营养检查调查（NHANES）中1476名参与者的数据，以及他们在美国农业部饮食研究食品和营养数据库（FNDDS）的类黄酮数据库中相关的大豆苷元摄入量，进行了一项横断面研究。我们通过二元逻辑回归模型和线性回归模型调整混杂变量，研究了MAFLD状态、受控衰减参数（CAP）、AST/血小板比值指数（APRI）、纤维化-4指数（FIB-4）、肝脏硬度测量（LSM）、非酒精性脂肪性肝病（NAFLD）纤维化评分（NFS）、肝脂肪变性指数（HSI）、脂肪肝指数（FLI）与大豆苷元摄入量之间的关系。
在多变量调整模型II中，大豆苷元摄入量与MAFLD的发病率呈负相关（Q4与Q1相比的OR为0.65，95%置信区间[CI]=0.46-0.91，=0.0114，趋势检验的P值为0.0190）。在调整年龄、性别、种族、婚姻状况、教育水平、家庭收入与贫困率（PIR）、吸烟和饮酒后，模型II中CAP也与大豆苷元摄入量呈负相关，= -0.37，95% CI：-0.63至-0.12，=0.0046。按大豆苷元摄入量的四分位数分层，大豆苷元摄入量与CAP之间关系的趋势分析仍然显著（趋势检验的P值=0.0054）。此外，我们还发现HSI、FLI和NFS与大豆苷元摄入量呈负相关。LSM与大豆苷元摄入量呈负相关，但无统计学意义。APRI、FIB-4与大豆苷元摄入量之间的相关性不强（尽管P<0.05，但β值均为0）。
我们发现，随着大豆苷元摄入量的增加，MAFLD患病率、CAP、HSI和FLI均降低，这表明大豆苷元摄入量可能改善肝脂肪变性。因此，食用大豆食品或补充剂的饮食模式可能是减轻疾病负担和降低MAFLD患病率的一种有价值的策略。
